Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for LLY and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for LLY and 80,000+ other tickers.
See exactly how LLY's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for LLY and 80,000+ other tickers.
Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basaglar, the Humalog family (e.g., Mix 75/25, U-100, U-200, Mix 50/50), insulin lispro products (including protamine and mix 75/25), and the Humulin line (e.g., 70/30, N, R, U-500). Furthermore, Eli Lilly provides specialized treatments for type 2 diabetes, such as Jardiance, Trajenta, and Trulicity…
President Donald Trump has announced that all generic drugs imported into the United States would continue to enjoy a zero-percent tariff for another two years, sending major drug stocks up.
IXJ offers a higher dividend yield and lower volatility with global exposure, while RSPH's equal-weight approach posted a stronger 1-year return.
Novo Nordisk A/S is suing rival drugmaker Eli Lilly & Co. for showing what it calls are misleading ads about obesity drugs in the US. Novo says Lilly is using outdated information when comparing Novo's Wegovy to Lilly's Zepbound.
CNBC's Jim Cramer delivers his daily Mad Dash.
Novo Nordisk has filed a lawsuit against Eli Lilly (LLY) in a US federal court, accusing its rival of running false and misleading advertising campaigns for its blockbuster diabetes and weight-loss drugs. The lawsuit, filed Tuesday in the US District Court for the District of New Jersey, alleges that Eli Lilly and Lilly USA violated federal and state false advertising and unfair competition laws, including the Lanham Act.